FI76216B - BESTAEMNINGSFOERFARANDE FOR ANTIGEN. - Google Patents

BESTAEMNINGSFOERFARANDE FOR ANTIGEN. Download PDF

Info

Publication number
FI76216B
FI76216B FI831095A FI831095A FI76216B FI 76216 B FI76216 B FI 76216B FI 831095 A FI831095 A FI 831095A FI 831095 A FI831095 A FI 831095A FI 76216 B FI76216 B FI 76216B
Authority
FI
Finland
Prior art keywords
antigen
buffer
reaction
antibody
polyethylene glycol
Prior art date
Application number
FI831095A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI831095L (en
FI76216C (en
FI831095A0 (en
Inventor
Josef Danninger
Reiner Spaethe
Original Assignee
Baxter Travenol Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Travenol Lab filed Critical Baxter Travenol Lab
Publication of FI831095A0 publication Critical patent/FI831095A0/en
Publication of FI831095L publication Critical patent/FI831095L/en
Publication of FI76216B publication Critical patent/FI76216B/en
Application granted granted Critical
Publication of FI76216C publication Critical patent/FI76216C/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Semiconductor Memories (AREA)
  • Amplifiers (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1. A method for determination of the antigen content of a sample by the antigen-antibody reaction, comprising diluting at least one of the two reaction components with a physiological saline solution, which contains polyethyleneglycol and a buffer substance, thereafter combining both reaction components and determining the antigen-antibody-reaction photometrically, characterized in that the buffer substance is a glycine, glycyl-glycine, acetate, citrate, N,N-bis-(2-hydroxyethyl)-glycine, histidine/HCl, 2-amino-2-(hydroxymethyl)- 1,3-propanol or 5,5-dialkyl-barbituric acid buffer.

Description

7621 67621 6

Antigeenien määritysmenetelmäMethod for the determination of antigens

Keksintö koskee menetelmää, jonka avulla voidaan määrittää näytteen antigeenipitoieuue antigeeni-vaeta-aine-reaktion perusteella patenttivaatimuksen 1 johdannon mukaisesti. Keksinnön kohteena on myös ohennusaine tämän menetelmän suorituksessa käytettäviä antigeeni- ja vasta-aine-reaktio-komponent-teja varten.The invention relates to a method for determining the antigen content of a sample on the basis of an antigen-antibody reaction according to the preamble of claim 1. The invention also relates to a diluent for the antigen and antibody reaction components used in carrying out this method.

Diagnostisesti tärkeiden parametrien määritys näytteessä, kuten seerumissa, plasmassa tai selkäydinnesteessä olevien antigeenien avulla, immunologisen tai antigeeni-vasta-aine-reaktion perusteella, joka tulkitaan fotometrisesti esimerkiksi nefelometrian tai turbidometriän avulla, vaatii usein molempien reaktiokomponenttien epesifisen esivalmistelun. Tällöin tavallisesti ohennetaan toinen reaktiokomponentti, joka sisältää näytteen, jonka antigeenipitoisuus on määrättävä ja toinen komponentti, joka sisältää vasta-aineen, joka siis tavallisesti muodostuu vastaavan antiseerumin vaikutuksesta, fysiologisella keittosuolaliuoksella tai fysiologisella keittosuolaliuoksella, joka sisältää lisäksi 4 X polyetylee-niglykolia (keskimääräinen molekyylipaino 6000).Determination of diagnostically important parameters by antigens in a sample, such as serum, plasma, or spinal fluid, based on an immunological or antigen-antibody reaction, which is interpreted photometrically by, for example, nephelometry or turbidometry, often requires specific preparation of both reaction components. In this case, the second reaction component containing the sample to be determined and the second component containing the antibody, which is thus usually formed by the action of the corresponding antiserum, is usually diluted with physiological saline or physiological saline solution further containing 4 X polyethylene niglycol (average ).

Polyetyleeniglykolipitoieuuden tarkoituksena on pääasiallisesti estää reaktiossa syntyvien antigeeni-vasta-aine-kom-pleksien höytäleinen saostuminen, so. sakan muodostuminen tes-tiliuoksessa, joka muodostuu yhdistettäessä molemmat reak-tiokomponentit antigeenimäärityksen eli mittauksen aikana.The purpose of the polyethylene glycol content is mainly to prevent the flocculent precipitation of the antigen-antibody complexes formed in the reaction, i. the formation of a precipitate in the test solution formed by combining the two reaction components during the antigen determination, i.e. the measurement.

Tämä polyetyleeniglykolin ominaisuus on ollut jo kauan tunnettu ja se on näiden mittausten perusedellytys, koska muuten ei voida saada mukaan kaikkia antigeeni-vaeta-aine-komplekse-ja mittauksen aikana.This property of polyethylene glycol has long been known and is a basic prerequisite for these measurements, as otherwise not all antigen-diluent complexes can be included during the measurement.

Kun immunoglobuliineja määritettiin laeerturbidometrian avulla seuraavan käsikirjan mukaan: "Arbeitsanleitung fur das 2 7621 6When immunoglobulins were determined by laser turbidometry according to the following manual: "Arbeitsanleitung fur das 2 7621 6

Laeermed-Turbidometer <pm 4) zur Beetimmung der Immunglobu-line IgA, IgG, IgM mit ATAB-Antieeren, Firma AHS Deutschland GmbH, Bereich Merz und Dada, Miinchen" , 1982, huomattiin, että eri fysiologiset keittosuolaliuokset, joissa oli 4 paino-X polyetyleeniglykolia, vaikka ne oli kulloinkin valmistettu saman reseptin mukaan, samoja kemikaaleja käyttäen ja saman henkilön tekeminä antoivat analyysin aikana erilaisia mitta-signaaleja laserturbidometrissä. Ei voitu siis saada riittävän tarkasti toistettavia tuloksia. Tällöin häiriytyi erikoisen paljon edellä mainitun työohjeen mukainen ns. kinetiikka-menetelmä, jossa mitataan esimerkiksi 10 sekunnin pituisen esireaktion jälkeen antigeeni-vasta-aine-reaktion nopeus ja määritetään sitten antigeenipitoisuus. Päinvastoin kuin mainitun työohjeen mukaisessa ns. "Fix point Methode'sea”, eli esimerkiksi 30 minuuttia kestävän reaktion päätepisteen mittauksessa, ei mainitussa kinetiikkamenetelmässä siis tarvitse odottaa koko antigeeni-vasta-aine-reaktion kulkua loppuun asti.Laeermed-Turbidometer <pm 4) zur Beetimmung der Immunglobu-line IgA, IgG, IgM mit ATAB-Antieeren, Firma AHS Deutschland GmbH, Bereich Merz und Dada, München ", 1982, it was found that various physiological saline solutions containing 4 wt. X polyethylene glycols, although prepared according to the same recipe, using the same chemicals and by the same person, gave different measurement signals on the laser turbidometer during the analysis, so that it was not possible to obtain reproducible results with sufficient accuracy, thereby disturbing the kinetics method according to the above instructions. In contrast to the so-called "Fix point Method" according to said protocol, i.e. for measuring the end point of a reaction lasting 30 minutes, the kinetic method thus does not, in particular, measure the rate of the antigen-antibody reaction after a pre-reaction of 10 seconds and then determine the antigen content. need to wait for the entire antigen-antibody reaction ion passage to the end.

Keksinnön avulla, jonka tunnusmerkit on esitetty patenttivaatimuksissa, ratkaistaan tehtävä saada aikaan menetelmä eli ohennusaine, jonka avulla antigeenipitoisuua jossakin näytteessä voidaan määrittää vieläpä kinetiikkamenetelmää noudattaen tarkasti ja uudelleen toistettavasti.The invention, the features of which are set out in the claims, solves the object of providing a method, i.e. a diluent, by means of which the antigen content in a sample can be determined accurately and reproducibly even according to a kinetic method.

Vasta-ainemolekyylissä on moniarvoinen ja sen vuoksi hyvin monimutkainen rakennemuoto, kun taas polyetyleeniglykoli on ei-polaarinen ja tämän vuoksi yksinkertainen rakenteeltaan.The antibody molecule has a polyvalent and therefore very complex structural form, while polyethylene glycol is non-polar and therefore simple in structure.

Kun nämä molemmat reaktiokomponentit yhdistetään, tapahtuu sen vuoksi määrätty homogeeninen jakaantuminen vasta pitkän ajan kuluttua ja saadaan jossakin määrin toistettavia analyysituloksia. Keksinnön mukainen menetelmä perustuu siihen, että saadaan aikaan molempien reaktiokomponenttien nopea ja homogeeninen jakaantuminen siten, että polyetyleeniglykoli-pitoiseen, fysologiseen keittosuolaliuokseen lisätään vielä 3 7 621 6 puskuriainetta, Joka poistaa vasta-ainemolekyylin monimutkaisen rakennemuodon tasottamalla varaukset.When these two reaction components are combined, therefore, a certain homogeneous distribution takes place only after a long time and to some extent reproducible analytical results are obtained. The method of the invention is based on providing a rapid and homogeneous distribution of both reaction components by adding an additional 3 7 621 6 buffer to the polyethylene glycol-containing physiological saline solution, which removes the complex structure of the antibody molecule by leveling the charges.

Yllättäen on käynyt ilmi, että antigeeni-vasta-aine-reaktion nopeus on riippuvainen erikoisesti puskurlaineen kemiallisesta kokoomuksesta, ja vieläpä paljon enemmän kuin puskuriai-neen konsentraatiosta tai pH-arvosta. Erikoisen tärkeätä on keksinnön yhteydessä se, ettei valita sellaisia puskuriainei-ta, jotka sallivat mahdollisimman nopean reaktionopeuden, vaan etupäässä sellaisia puskuriaineita, jotka johtavat pitemmän ajan vakiona pysyvään alkureaktionopeuteen. Keksinnön mukaisesti lisättävien puekuriaineiden tämän ominaisuuden kautta reaktion kestoaika nimittäin jonkin verran pitenee, niin että suoraviivaista etenemistä tapahtuu suhteellisen pitkän ajan. Tämän kautta paranee kinetiikkamenetelmän tulosten tarkkuus huomattavasti. Jos esimerkiksi lisätään 20 mmol/1 5,5-dietyylibarbituurihappoa, pH 7,5 puskuriksi fysiologiseen, 4 paino-% polyetyleeniglykolia sisältävään keittosuolaliuokseen, niin odotetaan molempien reaktiokomponenttien yhdistämisen jälkeen esimerkiksi 10 sekunnin esireaktion verran, johon liittyy esimerkiksi noin 30 sekunnin mittausaika. 30 sekunnin ajanjakso on sitten riittävä mittausperusta hyvin tarkoillekin mittaustuloksille antigeenimäärityksessä.Surprisingly, it has been found that the rate of the antigen-antibody reaction depends in particular on the chemical composition of the buffer, and even much more than on the concentration or pH of the buffer. In the context of the invention, it is particularly important not to select buffers which allow the fastest possible reaction rate, but above all buffer substances which lead to a constant initial reaction rate for a longer period of time. Namely, through this property of the wood curing agents to be added according to the invention, the reaction time is somewhat extended, so that a straightforward progression takes place for a relatively long time. This greatly improves the accuracy of the results of the kinetic method. For example, if 20 mmol / l of 5,5-diethylbarbituric acid, pH 7.5, is added as a buffer to a physiological saline solution containing 4% by weight of polyethylene glycol, then after combining both reaction components a pre-reaction of, for example, 10 seconds is expected, for example about 30 seconds. A period of 30 seconds is then a sufficient basis for even very accurate measurement results in an antigen assay.

Claims (7)

1. Förfarande mad vilkat proveta antigenhalt beetamme pä grund av en antigen-antikropperaaktion eä att ätminetona dan ana av deeea reaktionekomponantar utapäde mad an fyeiolo-giek kokealtloaning innahällande polyatylanglykol och buf- fertmedal, därefter bäda reaktionekomponantar föranae och antigan-antikropperaaktion beetamme fotomatriekt, kännatacknat av att buffartmadlet är 5,5-dialkylbarbitureyrabuffart.1. A method for testing the antigen content of beetame due to an antigen-antibody reaction or to exclude any of the reaction components from the anticoagulant cocaine release containing polyethylene glycol and buffer antigen, and the antigen antibody reaction component. that the buffer agent is 5,5-dialkyl barbiturate buffer. 2. Förfarande enligt patentkravat 1, kännatacknat av att barbitureyran är an 5,5-diatylbarbitureyra.2. A method according to claim 1, characterized in that the barbiturate is an 5,5-diatylbarbituric acid. 3. Förfarande enligt patentkravat 1 allar 2, känneteck-nat av att buffartmedlate koncentration i kokealtlöeningan är 5-200 mmol/1, foraträdaevie 20-50 mmol/1.3. A process according to claim 1, characterized in that the buffer-mediated concentration in the coke solution is 5-200 mmol / l, preferably 20-50 mmol / l. 4. Förfarande enligt nägot av patantkraven ovan, kännatacknat av att polyetylenglykolene koncentration i kokealtlöeningan är 2-6 vikt-X, företrädaevie cirka 4 vikt-X och polyetylenglykolene ganomenittliga molakylvikt är 4000-12 000, företrädaevie cirka 6000.4. A process according to any of the claims above, characterized in that the concentration of polyethylene glycolene in the cocaine solution is 2-6 wt. X, preferably about 4 wt. 5. Förfarande enligt nägot av patantkraven ovan, kännatacknat av att pH-värde av dan buffertmedal innehäl-landa polyatylanglykolhaltiga fyeiologieka kokealtlöeningan är 4,0-9,0 och företrädaevie 6,5-8.5. A process according to any of the claims above, characterized in that the pH value of the buffer medium containing the polyethylene glycol-containing physiological cocaine solution is 4.0-9.0 and preferably from 6.5-8. 6. Förfarande enligt nägot av patantkraven ovan, kännatacknat av att antigen-antikroppereaktionene kinatieka förlopp beetämmä fotomatriekt.6. A method according to any of the claims above, characterized in that the antigen-antibody reactions kinetically proceed with photometry. 7. Fyeiologiek kokealtloaning, eom innahällar polyety-langlykol och buffertmedal, eom utepädningeämna ätminetone i dan andra av tvä antigan-antikropperaaktione raaktionekompo-nantar, vilkae antigenhalt baetämme fotomatriekt, känneteck-nad av att buffartmadlet är 5,5-dialkylbarbitureyrabuffart.7. Phyiologic cocoanalysis, which contains polyethylene glycol and buffer medals, as well as dilute ether monetone in other of two antigen-antibody reaction reaction components, which antigen content may be photomatriched, characterized in that the buffer agent is 5.
FI831095A 1982-04-05 1983-03-30 Determination procedure for antigen FI76216C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3212658 1982-04-05
DE19823212658 DE3212658C3 (en) 1982-04-05 1982-04-05 METHOD FOR DETERMINING ANTIGEN

Publications (4)

Publication Number Publication Date
FI831095A0 FI831095A0 (en) 1983-03-30
FI831095L FI831095L (en) 1983-10-06
FI76216B true FI76216B (en) 1988-05-31
FI76216C FI76216C (en) 1988-09-09

Family

ID=6160289

Family Applications (1)

Application Number Title Priority Date Filing Date
FI831095A FI76216C (en) 1982-04-05 1983-03-30 Determination procedure for antigen

Country Status (8)

Country Link
EP (1) EP0090966B1 (en)
JP (1) JPH0650313B2 (en)
AT (1) ATE17049T1 (en)
CA (1) CA1208548A (en)
DE (1) DE3212658C3 (en)
ES (1) ES521137A0 (en)
FI (1) FI76216C (en)
IE (1) IE54400B1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61113271A (en) * 1984-11-08 1986-05-31 Matsushita Electronics Corp Semiconductor memory device
JPS62159047A (en) * 1985-12-31 1987-07-15 Chemo Sero Therapeut Res Inst Reagent for quantitative determination of plasma protein
US5371021A (en) * 1992-07-17 1994-12-06 Beckman Instruments, Inc. Initial rate photometric method for immunoassay
TWI842764B (en) * 2018-11-09 2024-05-21 日商積水醫療股份有限公司 Methods for suppressing abnormal detections in immunoassays conducted with an automatic analyzer, detection methods, immunoassay reagents, and immunoassay reagent kits

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1540098A (en) * 1975-03-06 1979-02-07 Baxter Travenol Lab Immunological reagent and nephelometric method of using same
JPS605899B2 (en) * 1975-04-10 1985-02-14 中外製薬株式会社 Immunochemical quantitative method
GB1590525A (en) * 1976-12-10 1981-06-03 Technicon Instr Biological analysis
JPS5399319A (en) * 1977-02-09 1978-08-30 Hidematsu Hirai Novel qualitative and quantitative detecting method and detecting body for antgenic substance
JPS582660A (en) * 1981-06-30 1983-01-08 Chugai Pharmaceut Co Ltd Immunological reagent
JPS5847256A (en) * 1981-09-14 1983-03-18 Mitsubishi Chem Ind Ltd Measuring method for antigen-antibody reaction

Also Published As

Publication number Publication date
EP0090966B1 (en) 1985-12-18
DE3212658C2 (en) 1987-11-26
FI831095L (en) 1983-10-06
JPS58182558A (en) 1983-10-25
DE3212658A1 (en) 1983-10-06
ES8402425A1 (en) 1984-01-16
CA1208548A (en) 1986-07-29
ATE17049T1 (en) 1986-01-15
JPH0650313B2 (en) 1994-06-29
IE54400B1 (en) 1989-09-27
ES521137A0 (en) 1984-01-16
FI76216C (en) 1988-09-09
EP0090966A1 (en) 1983-10-12
FI831095A0 (en) 1983-03-30
DE3212658C3 (en) 1993-08-19
IE830752L (en) 1983-10-05

Similar Documents

Publication Publication Date Title
JPH0785086B2 (en) Fluorescence polarization immunoassay and reagents used in the assay
US4255411A (en) Process of determining an immunogenic substance by competition with an antibody in a microcapsule
JP2008529024A (en) Method for quantitative determination of analytes in liquid samples by immunochromatography
EP0222341B1 (en) A method for immunoassay and reagents therefor
NO149864B (en) IMMUNOLOGICAL REAGENT.
CN101046479B (en) Process of preparing human serum base matter containing no target protein
JPS605899B2 (en) Immunochemical quantitative method
CN113125696A (en) Estradiol homogeneous phase chemiluminescence detection kit and application thereof
FI76216B (en) BESTAEMNINGSFOERFARANDE FOR ANTIGEN.
BRPI0414784B1 (en) METHOD AND DEVICE FOR DETECTION OF VERY SMALL PARTICULAR QUANTITIES
Blanchard et al. Two immunofluorescent methods compared with a radial immunodiffusion method for measurement of serum immunoglobulins.
US4307071A (en) Analytical reagent and method
CN113125731A (en) Competitive homogeneous phase chemiluminescence assay kit and application thereof
SU1367838A3 (en) Versions of method of determining tistreptolizene antibodies in blood
Slavik et al. The advantages and limitations of impedance aggregometry in detection of heparin-induced thrombocytopenia
CN103197062B (en) A kind of method and special ELISA reagent kit thereof detecting dioxin
JP3458251B2 (en) Chemiluminescence method using fibrous material for solid phase
JPH0274865A (en) Method of determining phosphorus in body fluid
CN113125415A (en) Competitive homogeneous phase chemiluminescence detection method and application thereof
JPH0814581B2 (en) Antigen or antibody quantification method
JPS63115061A (en) Immunoassay
JPS62207958A (en) Method and reagent for quantitative determination of antigen or antibody
JPH04309864A (en) Quantitative measurement for antigen or antibody
JPH03170864A (en) Method of measuring ligand by fluorescent polarization method
JPS63298061A (en) Determination of human c reactive protein

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: BAXTER INTERNATIONAL INC.